David Bowen
Impact in
- Hematology top 0.02%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
Papers in
- Hematology 187
- Acute Myeloid Leukemia Research 161
- Iron Metabolism and Disorders 14
- Erythropoietin and Anemia Treatment 13
- Hematopoietic Stem Cell Transplantation 13
-
- Cancer Genomics and Diagnostics 20
- Co-authors
- Alan K. Burnett (21 shared papers)Marion E. Frew (8 shared papers)David C. Linch (4 shared papers)Rosemary E. Gale (4 shared papers)Stephen E. Langabeer (4 shared papers)Panagiotis D. Kottaridis (3 shared papers)Keith Wheatley (9 shared papers)Anthony H. Goldstone (2 shared papers)
- Journals
- Blood (57 papers)British Journal of Haematology (34 papers)Leukemia Research (17 papers)Leukemia (13 papers)Nature Communications (12 papers)
- Partner nations
- United KingdomGermanyUnited States
In The Last Decade
David Bowen
238 papers receiving 27.8k citations
David Bowen's Hit Papers
Peers
Comparison fields: 5 of 147
- Hematology 13.9k
- Cancer Research 4.2k
- Genetics 2.1k
- Oncology 2.3k
- Molecular Biology 5.4k
Countries citing papers authored by David Bowen
This map shows the geographic impact of David Bowen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Bowen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Bowen more than expected).
Fields of papers citing papers by David Bowen
This network shows the impact of papers produced by David Bowen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Bowen. The network helps show where David Bowen may publish in the future.
Co-authors
The 25 scholars most cited alongside David Bowen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 244 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Revised International Prognostic Scoring System for Myelodysplastic Syndromes Hit paper breakdown → | 2012 | 2475 |
| 2 | The repertoire of mutational signatures in human cancer Hit paper breakdown → | 2020 | 2401 |
| 3 | Pan-cancer analysis of whole genomes Hit paper breakdown → | 2020 | 2169 |
| 4 | Clinical and biological implications of driver mutations in myelodysplastic syndromes Hit paper breakdown → | 2013 | 1552 |
| 5 | Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2 Hit paper breakdown → | 2013 | 1469 |
| 6 | The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Hit paper breakdown → | 2001 | 1332 |
| 7 | SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts Hit paper breakdown → | 2011 | 1036 |
| 8 | The evolutionary history of 2,658 cancers Hit paper breakdown → | 2020 | 730 |
| 9 | Patterns of somatic structural variation in human cancer genomes Hit paper breakdown → | 2020 | 564 |
| 10 | Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet Hit paper breakdown → | 2013 | 538 |
| 11 | Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia Hit paper breakdown → | 2011 | 525 |
| 12 | Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing Hit paper breakdown → | 2020 | 489 |
| 13 | 1993 | 433 | |
| 14 | Analyses of non-coding somatic drivers in 2,658 cancer whole genomes Hit paper breakdown → | 2020 | 428 |
| 15 | 2015 | 425 | |
| 16 | Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms Hit paper breakdown → | 2011 | 421 |
| 17 | Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes Hit paper breakdown → | 2020 | 419 |
| 18 | 2011 | 412 | |
| 19 | Comprehensive molecular characterization of mitochondrial genomes in human cancers Hit paper breakdown → | 2020 | 319 |
| 20 | Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition Hit paper breakdown → | 2020 | 315 |
About David Bowen
David Bowen is a scholar working on Hematology, Cancer Research, Biochemistry, Genetics and Oncology, having authored 244 papers that have together received 28.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (161 papers), Cancer Genomics and Diagnostics (20 papers), Iron Metabolism and Disorders (14 papers), Blood transfusion and management (14 papers), Erythropoietin and Anemia Treatment (13 papers), Hematopoietic Stem Cell Transplantation (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Cancer survivorship and care (8 papers). The work is most often cited by research in Hematology (13.9k citations), Cancer Research (4.2k citations), Genetics (2.1k citations), Oncology (2.3k citations) and Molecular Biology (5.4k citations). David Bowen has collaborated with scholars based in United Kingdom, Germany and United States. Frequent co-authors include Alan K. Burnett, Marion E. Frew, David C. Linch, Rosemary E. Gale, Stephen E. Langabeer, Panagiotis D. Kottaridis, Keith Wheatley, Anthony H. Goldstone, G Harrison and Pierre Fenaux. Their work appears in journals such as Blood, British Journal of Haematology, Leukemia Research, Leukemia and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.